Multiple sclerosis represents a debilitating neuroinflammatory condition that compromises both central neural conduction and systemic regulatory processes. While clinicians predominantly focus on motor and cognitive deterioration, autonomic failure frequently destabilizes epithelial homeostasis. In particular, impaired nasal mucociliary clearance emerges as an underrecognized manifestation in affected individuals. Respiratory tract defense relies directly on rhythmic ciliary motility and adequate sol-gel mucus hydration. Consequently, structural or autonomic alterations diminish the clearance of inhaled pathogens and chemical toxins. Recent cross-sectional investigations demonstrate that mucosal transit time lengthens markedly as central neurodegeneration advances across clinical phenotypes.

Understanding Nasal Mucociliary Clearance in Neurological Disease

Respiratory cilia coordinate synchronized metachronal waves to propel entrapment mucus toward the nasopharynx. Therefore, intact autonomic neurovascular signaling remains essential to modulate secretion volume, fluid viscosity, and ciliary beat frequency. When central demyelinating pathways interrupt sympathetic or parasympathetic inputs, mucosal surfaces suffer significant functional decline. In clinical otorhinolaryngology, investigators traditionally evaluate this vital physiologic barrier using the standardized saccharin transit test. Healthy individuals clear particles efficiently within normal physiological windows. Conversely, patients diagnosed with neurodegenerative pathology frequently exhibit delayed transit intervals. This reduction in clearance velocity exposes the upper respiratory epithelium to persistent colonization. Consequently, chronic pathogenic exposure heightens mucosal inflammation and predisposes susceptible hosts to recurrent infections. Clinicians must recognize that upper airway vulnerability often reflects broader autonomic compromise. As a result, assessing mucosal integrity offers meaningful diagnostic clues regarding the degree of systemic neuroaxonal impairment.

Autonomic Dysfunction and Mucosal Defense in Multiple Sclerosis

Central demyelination in multiple sclerosis regularly damages brainstem autonomic nuclei, medullary pathways, and spinal cord intermediolateral columns. Consequently, abnormal sympathetic-parasympathetic tone disrupts glandular serous secretion and alters microvascular mucosal perfusion. Because intact autonomic innervation governs mucociliary velocity, neural lesions inevitably degrade epithelial barrier defense. Furthermore, chronic neuroinflammation promotes localized oxidative stress that damages motile respiratory cilia directly. Patients suffering from progressive disease phenotypes generally display more pronounced autonomic deficits than individuals with early relapsing disease. Accordingly, prolonged clearance times appear consistently in cohorts with extensive neuroaxonal loss. In addition, persistent mucus stasis facilitates microbial adherence, creating a permissive environment for opportunistic respiratory pathogens. Therefore, impaired mucosal transport represents a distinct pathophysiological consequence of widespread central autonomic network failure. Recognizing these autonomic underpinnings helps clinicians understand why respiratory complications emerge during advanced disease stages.

Evaluating Disease Severity and Nasal Transport Kinetics

Clinical investigations demonstrate a direct correlation between prolonged transit intervals and higher Expanded Disability Status Scale scores. Specifically, individuals experiencing secondary progressive or primary progressive multiple sclerosis exhibit greater clearance delays than relapsing-remitting cohorts. Moreover, longer disease duration independently associates with progressive mucociliary deceleration, reflecting cumulative structural neurological damage. Patients with severe physical disability often display shallow tidal ventilation, diminished cough reflexes, and compromised pharyngeal clearance mechanisms. Consequently, delayed nasal transport compounds lower airway vulnerabilities and increases pneumonia risk. Routine otorhinolaryngological evaluations frequently reveal dry mucosal membranes, crusting, and subclinical inflammatory remodeling in severely disabled patients. Therefore, measuring mucosal clearance kinetics yields practical physiological insight into systemic disease burden. Furthermore, establishing baseline clearance measurements assists clinicians in identifying individuals who require aggressive respiratory protection strategies.

The Impact of Disease-Modifying Therapies on Respiratory Mucosa

Modern multiple sclerosis management utilizes diverse disease-modifying therapies that modulate systemic and mucosal immune surveillance. Recent comparative analyses have examined whether agents like ocrelizumab and fingolimod influence mucociliary transit parameters differentially. A recent erratum corrected typographical labeling between treatment cohorts, confirming that patients on high-efficacy therapies frequently exhibit significantly lengthened clearance intervals. However, clinicians must interpret these pharmacologic observations with appropriate contextual caution. Individuals receiving anti-CD20 monoclonal antibodies or sphingosine-1-phosphate receptor modulators typically present with higher baseline disability and aggressive disease biology. Thus, advanced disease stage rather than direct drug toxicity likely explains much of the observed clearance prolongation. Nevertheless, potent immunosuppression combined with sluggish mucosal clearance substantially increases the clinical severity of upper respiratory tract infections. Monitoring epithelial defenses during high-efficacy therapy remains essential for optimizing long-term safety.

Clinical Implications and Infection Prevention for Indian Physicians

Practitioners managing multiple sclerosis across India encounter distinctive environmental challenges that exacerbate mucosal dysfunction. High ambient particulate pollution, extreme seasonal humidity shifts, and crowded urban settings intensify respiratory mucosal stress. Because sluggish clearance hinders pollutant filtration, patients face heightened vulnerability to secondary bacterial rhinosinusitis and pulmonary infections. Furthermore, respiratory infections represent notorious triggers for demyelinating relapses and pseudo-exacerbations. Therefore, physicians should proactively integrate upper airway assessments into standard neurological follow-ups. Simple supportive measures, such as isotonic nasal saline irrigations, adequate systemic hydration, and humidification, significantly improve mucosal rheology. Additionally, timely immunization against influenza and pneumococcus provides crucial protection for immunocompromised cohorts. By addressing mucosal barrier health alongside central neurological therapy, clinicians deliver truly comprehensive, preventive clinical care.

Frequently Asked Questions

How does multiple sclerosis compromise nasal mucosal clearance?

Multiple sclerosis damages central autonomic pathways within the brainstem and spinal cord, disrupting sympathetic and parasympathetic regulation of nasal submucosal glands. Consequently, abnormal fluid secretion, increased mucus viscosity, and disrupted ciliary beat frequency impair effective particulate transport. Furthermore, persistent neuroinflammation generates systemic oxidative stress that damages motile respiratory cilia directly.

Why is monitoring upper airway mucosal health critical in progressive disease?

Patients with progressive forms of the disease carry higher disability scores and extended clearance delays. Because impaired clearance promotes microbial colonization, these vulnerable individuals face heightened risks of severe upper and lower respiratory infections. Prompt detection of mucosal stasis enables early preventive interventions, reducing infection-triggered relapses and hospitalizations.

How do disease-modifying therapies affect respiratory epithelial defense?

Disease-modifying therapies selectively suppress targeted lymphocyte populations, diminishing local mucosal immune responses against inhaled pathogens. Although prolonged clearance primarily reflects underlying disability severity, immunosuppressed individuals cannot clear adhering bacteria efficiently. Therefore, clinicians must maintain vigilance for opportunistic respiratory infections in patients receiving high-efficacy therapies.

Disclaimer: This content is for informational and educational purposes only and should not be construed as medical advice. Always seek the advice of a physician or other qualified health provider regarding clinical decision-making. Refer to the latest local and national guidelines for clinical practice.

References

Baydar C et al. Errate: Nasal Mucociliary Clearance and Its Relationship With Disease Severity in Patients With Multiple Sclerosis. Med Sci Monit. 2026 Sep 15. doi: 10.12659/MSM.955360. PMID: 42740694.

Baydar C, Yalınkılıç A, Çetin YS. Nasal Mucociliary Clearance and Its Relationship With Disease Severity in Patients With Multiple Sclerosis. Med Sci Monit. 2026; 32:e952850. doi: 10.12659/MSM.952850.

Habesoglu M, Habesoglu TE, Karatas B, et al. Assessment of nasal mucociliary clearance in patients with autonomic dysfunction. Am J Rhinol Allergy. 2017; 31(4):241-245.

Luna G, Alping P, Burman J, et al. Infection risks among patients with multiple sclerosis treated with disease-modifying therapies. JAMA Neurol. 2020; 77(2):184-191.